Total Payments
$2,356
2024 Payments
$2,164
Companies
3
Transactions
20
Payment Breakdown by Category
Research$2,164 (91.9%)
Food & Beverage$191.96 (8.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,164 | 14 | 91.9% |
| Food and Beverage | $191.96 | 6 | 8.1% |
Payments by Type
Research
$2,164
14 transactions
General
$191.96
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,164 | 14 | $0 (2024) |
| kaleo, Inc. | $104.54 | 5 | $0 (2023) |
| Seqirus USA Inc | $87.42 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,164 | 14 | ABBVIE INC. ($2,164) |
| 2023 | $111.02 | 2 | Seqirus USA Inc ($87.42) |
| 2022 | $56.90 | 3 | kaleo, Inc. ($56.90) |
| 2021 | $24.04 | 1 | kaleo, Inc. ($24.04) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $1,027.53 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | — | — | In-kind items and services | $154.94 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $69.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $125.05 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $70.25 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $37.47 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 04/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 08/14/2023 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Allergy | ||||||
| 03/17/2023 | Seqirus USA Inc | — | Food and Beverage | In-kind items and services | $87.42 | General |
| 08/16/2022 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Allergy | ||||||
| 05/16/2022 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Allergy | ||||||
| 03/29/2022 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Allergy | ||||||
| 09/27/2021 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: ALLERGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $2,164 | 14 |
About Therese Bernstein, APRN
Therese Bernstein, APRN is a Family healthcare provider based in Old Greenwich, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2013. The National Provider Identifier (NPI) number assigned to this provider is 1033459334.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Therese Bernstein, APRN has received a total of $2,356 in payments from pharmaceutical and medical device companies, with $2,164 received in 2024. These payments were reported across 20 transactions from 3 companies. The most common payment nature is "" ($2,164).
Ad
Practice Information
- Specialty Family
- Other Specialties Pediatrics
- Location Old Greenwich, CT
- Active Since 02/22/2013
- Last Updated 02/22/2013
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1033459334
Products in Payments
- ARMOUR THYROID (Drug) $1,947
- AUVI-Q (Drug) $104.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.